Compare KKR & Co Inc (KKR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Mesoblast Limited — how do they compare? KKR & Co Inc trades at $90.95 (market cap $80.39B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: KKR & Co Inc is far larger — about 45.9× Mesoblast Limited's market cap, and KKR & Co Inc pays a 0.87% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Mesoblast Limited for 15 Days on average.
| KKR | MESO | |
|---|---|---|
Market Cap | $80.39B | $1.75B |
Volume | 6,517,705 | 239,027 |
Sector | Financials | Health |
52-Week High | $142.75 | $20.96 |
52-Week Low | $83.88 | $13.19 |
Typical Hold Time | 67 Days | 15 Days |
Enterprise Value | $2.95B | $1.83B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $89.56, down 0.12% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. Recent earnings show a mixed track record, with Q2 2026 beating estimates but Q4 2025 missing. The company maintains strong analyst support with a consensus price target of $123.30 and 24 buy ratings. Recent news highlights active deal-making, including a joint venture with Thomson Reuters and investments in AI infrastructure, signaling ongoing strategic expansion.
The outlook for KKR is positive based on robust analyst sentiment and strategic investments, but risks include volatile cash flows and high debt levels. Investors may find opportunity in the significant upside to the price target, though macroeconomic sensitivity and execution risks warrant caution.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
